

(43) International Publication Date
12 November 2009 (12.11.2009)

PCT

(10) International Publication Number
WO 2009/137086 A1

(51) International Patent Classification:

A61K 31/485 (2006.01) A61P 1/00 (2006.01)
A61K 31/765 (2006.01) A61P 25/04 (2006.01)

(21) International Application Number:

PCT/US2009/002856

(22) International Filing Date:

7 May 2009 (07.05.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/126,868 7 May 2008 (07.05.2008) US

(71) Applicant (for all designated States except US): **NEKTAR THERAPEUTICS** [US/US]; 201 Industrial Road, San Carlos, CA 94070 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BRODBECK, Kevin, J.** [US/US]; 2383 South Court Street, Palo Alto, CA 94301 (US). **KUGLER, Alan, R.** [US/US]; 1250 Sunshine Valley Road, Montara, CA 94037-0961 (US).

(74) Agents: **WILSON, Mark, A.** et al.; NEKTAR THERAPEUTICS, 201 Industrial Road, San Carlos, CA 94070 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: ORAL ADMINISTRATION OF PERIPHERALLY-ACTING OPIOID ANTAGONISTS




FIG 1

(57) Abstract: Peripherally-acting opioid antagonists can be orally administered to treat the side effects of opioid administration in convenient dosing schedules.